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Background: Cardiovascular disease and mental health both hold enormous public health importance, both
ranking highly in results of the recent Global Burden of Disease Study 2010 (GBD 2010). For the first time, the GBD
2010 has systematically and quantitatively assessed major depression as an independent risk factor for the
development of ischemic heart disease (IHD) using comparative risk assessment methodology.
Methods: A pooled relative risk (RR) was calculated from studies identified through a systematic review with strict
inclusion criteria designed to provide evidence of independent risk factor status. Accepted case definitions of
depression include diagnosis by a clinician or by non-clinician raters adhering to Diagnostic and Statistical Manual
of Mental Disorders (DSM) or International Classification of Diseases (ICD) classifications. We therefore refer to the
exposure in this paper as major depression as opposed to the DSM-IV category of major depressive disorder (MDD).
The population attributable fraction (PAF) was calculated using the pooled RR estimate. Attributable burden was
calculated by multiplying the PAF by the underlying burden of IHD estimated as part of GBD 2010.
Results: The pooled relative risk of developing IHD in those with major depression was 1.56 (95% CI 1.30 to 1.87).
Globally there were almost 4 million estimated IHD disability-adjusted life years (DALYs), which can be attributed to
major depression in 2010; 3.5 million years of life lost and 250,000 years of life lived with a disability. These findings
highlight a previously underestimated mortality component of the burden of major depression. As a proportion of
overall IHD burden, 2.95% (95% CI 1.48 to 4.46%) of IHD DALYs were estimated to be attributable to MDD in 2010.
Eastern Europe and North Africa/Middle East demonstrate the highest proportion with Asia Pacific, high income
representing the lowest.
Conclusions: The present work comprises the most robust systematic review of its kind to date. The key finding
that major depression may be responsible for approximately 3% of global IHD DALYs warrants assessment for
depression in patients at high risk of developing IHD or at risk of a repeat IHD event.
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Cardiovascular disease and mental health both hold
enormous public health importance. Globally, they have
both ranked highly in terms of burden of disease and
prevalence [1]. In the most recent Global Burden of
Disease 2010 Study (GBD 2010) ischemic heart disease
(IHD) and stroke rank first and third, respectively, in
terms of disability-adjusted life years (DALYs), while
major depressive disorder (MDD) ranked 11th out of
291 disease and injuries [2]. These disorders have all in-
creased in ranking positions since 1990 estimates. When
considering the morbidity component alone, 5 mental
disorders (MDD, anxiety, bipolar disorder, schizophrenia
and dysthymia) feature in the top 20 causes of years
lived with disability (YLD).
Although disorder-specific GBD 2010 estimates can be
used to guide health policy and planning, estimates of
the additional burden due to disorders that are risk
factors provide an additional evidence base for develop-
ing preventative health policy. The Comparative Risk
Assessment (CRA) component of the GBD 2010 is a
systematic and quantitative assessment of changes in
population health that would result from modifying the
population distribution of exposure to a risk factor or a
group of risk factors [3,4]. The GBD 2010 is the first to
include mental disorders as independent risk factors for
other health outcomes globally. Quantifying the propor-
tion of health outcomes attributable to mental disorders
has thus far been neglected.
The association between major depression and IHD is
well documented [5-14]; however, previously applied re-
view methodologies have not robustly tested the tem-
poral relationship between major depression and IHD,
which is essential for clarifying the potential role of de-
pression as an independent risk factor for IHD given the
well-established bidirectional relationship between these
two diseases. There is increasing evidence for conside-
ring depression as an independent risk factor in the de-
velopment of IHD. A detailed rationale for examining
major depression as an independent risk factor for the
development of IHD, rather than an association, has
been discussed elsewhere [15]. Temporal and dose–res-
ponse relationships have been proposed in the literature,
as well as plausible behavioral and biological pathways.
However the possibility remains that depression could
be a non-causal risk marker in IHD [16].
This study aims to systematically and quantitatively as-
sess major depression as an independent risk factor for
the development of IHD. We present findings from a
systematic review of the literature and estimate the over-
all risk of developing IHD in those suffering from major
depression, estimate number of cases of IHD in the
population which may be caused by major depression,
and report the disease burden of IHD attributable tomajor depression. These calculations are presented for
21 world regions, both sexes, 11 age groups, and for
1990, 2005 and 2010 time periods.
Methods
Case definitions
According to Diagnostic and Statistical Manual of Men-
tal Disorders, fourth Edition (DSM-IV) criteria, MDD is
characterized by one or more major depressive episodes
lasting for at least 2 weeks [17,18]. There is acknow-
ledgement in the literature that the heterogeneity of de-
pression has implications for research [19]. We reduced
this heterogeneity by requiring a case definition of MDD
in the studies analyzed to be diagnosis by a clinician or
by non-clinician raters adhering to DSM or Interna-
tional Classification of Diseases (ICD) diagnostic classifi-
cations [20]. For studies that used symptom scales, we
required that these map to DSM/ICD diagnostic thresh-
olds as determined by consensus of three of the authors.
As we accept measures that are not strictly diagnostic,
we will refer to the exposure in this paper as major
depression (that is, presence of moderate to severe dep-
ressive symptoms) as opposed to the DSM-IV category
of MDD.
Similarly, we draw upon the ICD coding scheme for
our case definition of IHD. In line with the basic GBD
definitions of IHD we accepted cases of ICD-9 codes
410 to 414 or ICD-10 codes I20 to I25 [21]. Angina pec-
toris alone was not considered an acceptable proxy for
IHD due to its subjective nature and usual measurement
by self-report alone. However, it was expected that an-
gina (ICD-9 413 and ICD-10 120) would be included in
the IHD case definition of many studies. Study estimates
that included cases determined by self-report, physician
panel review of medical records, or ICD codes other
than previously mentioned were also taken into consi-
deration and accepted after discussion and consensus
with other investigators. Myocardial infarction (MI) was
considered to be an acceptable proxy for IHD and the
World Health Organization (WHO) 2007 criteria for MI
were accepted [22]. Consistent with the GBD 2010 def-
inition of IHD, asymptomatic (‘silent’) IHD captured by
electrocardiogram or cardiac imaging were not included.
In this work, we have taken the term ischemic heart
disease to be interchangeable with the commonly used
term coronary heart disease [19].
Search strategy
A systematic review was conducted to ascertain papers
reporting on IHD associated with major depression
that met predetermined inclusion and exclusion criteria
(Table 1). Recommendations from the Preferred Re-
porting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Statement 2009 were taken into account
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Meets the pre-determined case
definitions of major depression and IHD
Cross-sectional study design
Longitudinal case–control or cohort
study design
Clinical samples, for example,
studies using hospital data
Sampling is from the general population
Demographic characteristics of sample
represent populations at risk
Estimate of risk and associated
uncertainty/error is reported, or sufficient
data is reported to allow calculations of
these
Where multiple papers draw on the
same sample, the most comprehensive
or recent publication is preferred
Subjects with clinical manifestations of
IHD at baseline should be excluded or, at
the very least, controlled or stratified for
in the analysis
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a two-stage process. The first stage comprised a sys-
tematic search of the peer-reviewed literature. The next
stage of the search involved identifying review articles,
meta-analyses, editorials and resource books most pertin-
ent to this disorder and examining the reference list of
each to identify any further data sources. Data extracted
from papers included study descriptors (for example, de-
sign, sample ascertainment, location, representativeness),
sample descriptors (for example, age, gender, rural or
urban), exposure and outcome parameters (for example,
case definitions, diagnostic criteria, type of estimate,
period of follow-up, estimate error) and confounding fac-
tors controlled for in the analysis. Further details of the
search strategy and systematic review can be found in
Additional file 1.
Meta-analysis
MetaXL software version 0.1 (http://www.epigear.com),
a meta-analysis add-in for Microsoft Excel, was used to
pool RR estimates from individual studies. A ‘quality ef-
fects model’ was chosen in addition to the random effects
models to explicitly address heterogeneity between stud-
ies [24,25] (see Additional file 2 for quality checklist).
The random effects model is usually chosen over a fixed
effects model when there is significant heterogeneity
across studies as it incorporates an estimate of between-
study variation into the analysis [23]. Since the quality ef-
fects model weighs studies based on both the study quality
and the sample size it is able to control for variability due
to true differences in RR estimates and also differences
due to study quality [17,18,26].
Sensitivity analyses were also conducted using MetaXL
to test the effect of individual studies on the overallpooled estimate by removing one datapoint from the
sample at a time. Meta-analyses were stratified by inde-
pendent variables of interest, that is, sex and fatality
(fatal vs non-fatal IHD event). Publication bias was in-
vestigated by means of funnel plots.
Attributable burden estimation
The fundamental approach for the GBD 2010 compa-
rative risk assessment is to estimate the proportion of
deaths or disease burden caused by specific risk factors
while holding other independent factors constant. Be-
cause most diseases are caused by multiple factors, and
because some risk factors act through other, more pro-
ximal factors, population attributable fractions for mul-
tiple risk factors for the same disease can add to more
than 100%. In other words, the burden attributable to
different risks overlaps because of multicausality and be-
cause the effects of some risk factors are partly mediated
through other, more proximal, risks [3,4].
Using counterfactual analysis, the effect of a risk factor
can be quantified by comparing the burden associated to
an outcome with the amount that would be expected in
a hypothetical situation of ‘ideal’ risk factor exposure (in
this case, a world without major depression). The end
result is known as a population attributable fraction (PAF)
[27-29]. This approach provides a consistent method for
estimating the changes in population health as a function
of decreasing or increasing the level of exposure to risk
factors [29]. It should be noted that the terms population
attributable risk (PAR) (expressed as a proportion) and
PAF are synonymous and interchangeable [30]. For GBD
purposes we will use PAF.
PAFs associated with major depression as a risk factor
for IHD was calculated using the pooled RR estimates.
For more information on the prevalence data, refer to
the Mental Disorders Research Group’s reports on the
methodology and results for compiling epidemiological
data for mental disorders http://qcmhr.uq.edu.au/re-
search/policy-and-epidemiology/peabod/burden-of-dis-
ease/. The PAF was calculated using the following equation:
PAF ¼ p RR−1ð Þ
1þ p RR−1ð Þ
Where P is the prevalence of major depression and
RR is the corresponding pooled relative risk estimate
of IHD.
In the absence of evidence of differing risk between
age, gender or morbidity versus mortality our pooled RR
was applied across all groups. Prevalence data was esti-
mated separately for each country, age, sex and year
group, resulting in PAFs for each group [31]. In line with
findings in the literature it was decided to apply the
pooled RR to adults over 30 years of age only and as
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less than 30 years of age.
Attributable burden is calculated by multiplying the
PAF by the underlying burden. The burden due to IHD
was estimated as part of the Global Burden of Disease
Study 2010 [2]. Further details on the estimation of IHD
burden are available elsewhere [21]. In order to reflect
the uncertainty in our estimates, we calculated 1,000
draws each from the posterior distributions of the preva-
lence of MDD for each group, the relative risk, and the
IHD burden for each group. We assumed independence
between the uncertainty in these quantities and com-
puted the attributable burden for each of the 1,000 sets.
We report the mean and 2.5th and 97.5th centile values
of these draws.
Results
Systematic search and meta-analysis
A total of 8 studies examining major depression as a risk
factor for IHD met the inclusion criteria (Table 1) pro-
viding a total of 13 effect size estimates for analysis (see
Additional files 3 and 4 for search flow diagram and
summary of studies). The data represents observations
from a collective sample size of over 35,000 subjects.
One study was from The Netherlands [32], all other
studies originated from the USA. Two studies were na-
tionally representative [33,34]. Three studies were of
older samples (over 50 years of age) [32,34,35]. The mi-
nimum length of follow-up was 4 years and extended to
37 years. Three studies employed a measurement of major
depression that can be deemed truly diagnostic. The re-
maining studies all used the Center for EpidemiologicFigure 1 Pooled relative risk of incident ischemic heart disease (IHD)Studies Depression Scale (CES-D) and a symptom thres-
hold to determine presence of major depression.
Overall, major depression was associated with a sig-
nificantly elevated risk of incident IHD. Using a random
effects model, the pooled relative risk was 1.56 (95% CI
1.30 to 1.87) (Figure 1). There was little difference in re-
sults using the quality effects model (RR 1.54 (95% CI
1.27 to 1.87)), therefore we opted to continue analyses
using the random effects model. Sensitivity analysis re-
moving one datapoint from the sample at a time yielded
RRs ranging from 1.49 (95% CI 1.24 to 1.89) to 1.66
(95% CI 1.34 to 2.04). All results remain statistically sig-
nificant and show a comparably elevated risk for IHD.
Three estimates where IHD case definitions included
ICD 9 code 429 (ill-defined descriptions and complica-
tions of heart disease) or self-report were included in
the analyses based upon reviewer consensus. Removal of
these data points from the analysis demonstrated no im-
pact on overall relative risk (1.56 (95% CI 1.28 to 1.89)).
A test for heterogeneity of the entire dataset demon-
strates a relatively high degree of heterogeneity with an
I2 statistic of 67.1% (P = 0.000). A possible publication
bias was identified showing there may be some bias to-
wards studies with positive results (see Additional file 5).
Stratification of risk estimates for a fatal IHD event
versus a non-fatal outcome yielded non-significant dif-
ferences (non-fatal IHD (RR 1.8, 95% CI 1.34 to 2.65),
fatal events (RR 1.54, 95% CI = 0.85 to 2.80), and all
events (RR 1.51, 95% CI 1.19 to 1.90). Further stratifi-
cation of results, for example, by gender were severely
limited by insufficient data; however, exploratory ana-
lyses indicated a large difference in effect size, dependentcaused by major depression, random effects model.
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diagnosis inferring a greater relative risk for the develop-
ment of IHD (RR 2.50, 95% CI 1.73 to 3.60 versus RR
1.40, 95% CI 1.17 to 1.68).
Burden of disease
A summary of regional and global burden of disease es-
timates is presented in Table 2. Globally there were al-
most 4 million estimated IHD DALYs that can be
attributed to major depression in 2010. The overwhelm-
ing majority of this burden is attributed to years of life
lost (3.5 million years of life lost (YLL)) with a much
smaller component of IHD morbidity (250,000 YLD). As
a result, we now see a mortality component to major de-
pression burden as a risk factor that was not apparent
from estimates of the burden of major depression as a
disease (YLL was estimated to be 0) [36].
Absolute IHD DALYs attributable to major depression
in 2010 ranged from approximately 4,000 DALYs in
Oceania to 900,000 in South Asia. The lowest regions
across all three timepoints were Oceania, Australasia
and Latin America, Andean (see Additional file 6). The
highest were Eastern Europe and South Asia, this being
driven by large IHD burden and large population size,Table 2 Attributable ischemic heart disease (IHD) burden esti
Region Disability-adjusted life years
Asia Pacific, High Income 39,982 (19,701 to 66,462)
Asia, Central 112,925 (57,161 to 177,173)
Asia, East 386,610 (186,346 to 616,455)
Asia, South 863,351 (429,292 to 1,375,835)
Asia, Southeast 263,285 (135,382 to 421,193)
Australasia 9,622 (4,870 to 15,408)
Caribbean 29,484 (14,661 to 46,004)
Europe, Central 137,495 (69,706 to 214,634)
Europe, Eastern 664,145 (321,237 to 1,063,148)
Europe, Western 284,320 (144,755 to 435,735)
Latin America, Andean 12,761 (6,305 to 20,517)
Latin America, Central 84,115(43,308 to 132,587)
Latin America, Southern 31,373 (15,066 to 53,307)
Latin America, Tropical 127,581 (65,215 to 208,633)
North Africa/Middle East 363,828 (183,937 to 571,914)
North America, High Income 244,716 (125,676 to 394,058)
Oceania 3,628 (1,751 to 6,339)
SubSaharan Africa, Central 28,336 (13,710 to 47,204)
SubSaharan Africa, East 62,438 (31,898 to 99,496)
SubSaharan Africa, Southern 18,385 (9,071 to 30,166)
SubSaharan Africa, West 54,615 (27,511 to 86,304)
Global 3,823,004 (1,942,771 to 5,778, 350)respectively. Importantly for all regions, uncertainty
ranges for each timepoint overlap.
The overall age pattern shows a steady increase in at-
tributable burden that peaks at around 60 years of age
(Figure 2). The sharp rise in attributable DALYS in the
older ages is reflective of the significant rise in IHD bur-
den in this group [37]. As expected, males demonstrate
higher burden of IHD attributable to major depression
than females; however, this is only maintained until
around age 80. Note the apparent sudden increase in
DALYs after age 80 in females is an artifact of an 80+
age group (as opposed to a 5-year age group). The drop
in burden seen at around 60 years of age for males is ex-
plained by a moderately high (and peak) IHD death rate
in middle age coupled with large population at risk at
those ages, despite a higher IHD death rate at older ages.
Female IHD risk accelerates around age 65 years and ex-
plains the late rise in DALYs. It is important to note that
uncertainty bounds around male and female estimates
are large and overlapping.
The IHD burden attributable to major depression has
increased over time from 3.0 million DALYs in 1990 to
3.8 million DALYs in 2010 (Figure 3). However, the ma-
jority of this increase occurred in the 1990 to 2005mates by region, 2010 (95% CI)
Years of life lost Years lived with a disability
33,769 (16,218 to 56,464) 6,212 (2,413 to 12,936)
108,331 (54,721 to 170,514) 4,593 (1,983 to 8,725)
347,277 (164,890 to 550,414) 39,332 (17,416 to 70,703)
829,281 (411,750 to 1,325,451) 34,069 (15,321 to 60,095)
245,258 (125,893 to 395,411) 18,026 (7,955 to 32,258)
8,541 (4,344 to 13,721) 1,081 (421 to 2,028)
27,773 (13,791 to 43,647) 1,710 (728 to 3,224)
129,873 (65,902 to 202,094) 7,621 (3,384 to 14,119)
639,605 (308,328 to 1,023,931) 24,540 (10,754 to 43,824)
252,487 (127,659 to 387,169) 31,833 (13,996 to 56,870)
11,495 (5,747 to 18,348) 1,266 (529 to 2,470)
77,860 (39,465 to 122,414) 6,255 (2,652 to 12,031)
28,547 (13,876 to 47,362) 2,825 (1,140 to 5,412)
115,548 (58,951 to 191,580) 12,032 (5,224 to 21,858)
342,820 (171,720 to 533,404) 21,008 (9,630 to 37,854)
223,728 (114,409 to 358,292) 20,987 (9,588 to 38,059)
3,355 (1,623 to 5,891) 272 (107 to 507)
26,682 (12,849 to 44,673) 1,653 (667 to 3,421)
55,098 (28,007 to 88,043) 7,340 (3,205 to 13,455)
16,567 (8,175 to 27,355) 1,817 (771 to 3,341)
48,864 (24,879 to 76,381) 5,750 (2,483 to 11,008)
3,572,770 (1,791,433 to 5,411,987) 250,233 (114,845 to 444,063)
Figure 2 Global ischemic heart disease (IHD) disability-adjusted life years (DALYs) attributable to major depression by age and
sex, 2010.
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2005 and 2010. This overall increase is reflective of an
increase in IHD DALYs largely driven by population
growth and aging [37].
Mirroring observations made in IHD deaths, the over
80s contribute most to the burden increase [37]. Nearly
50% of DALYs are in the over 65s and approximately
80% in over 50s.
Presenting IHD DALYs attributable to major depres-
sion as an age-standardized and sex-standardized rate fa-
cilitates comparisons between regions (Figure 4). There
appears a disproportionate burden in Eastern Europe,
Central Europe and Central Asia with sub-SaharanFigure 3 Change in ischemic heart disease (IHD) disability-
adjusted life years (DALYs) attributable to major depression
over time, by age.Africa, East and West falling to the lower rankings
(see Additional file 7).
Time trends are not consistent across regions with
some regions experiencing an increase in DALY rates
across the timepoints and others experiencing a decline
(Figure 4). The exceedingly high rates seen in Eastern
Europe and Central Asia (former Soviet Union states)
are partnered with an increase over time. Increasing
trends over time are also observed in the remaining
Asian regions (South, East and Southeast), Oceania and
parts of Latin America. Encouragingly, all other regions
have demonstrated a reduction in attributable burden
since 1990.
As a proportion of overall IHD burden, 2.95% (95% CI
1.48% to 4.46%) of IHD DALYs were estimated to be at-
tributable to MDD in 2010. Eastern Europe and North
Africa/Middle East demonstrate the highest proportion
with Asia Pacific, high income representing the lowest
(Figure 5). These percentage estimates are reflective of a
function of both regional IHD prevalence and mortality
and major depression prevalence patterns where a
higher prevalence of MDD in the population will result
in a higher proportion of IHD cases being attributable to
major depression. For this reason we see the higher
MDD prevalence regions of North Africa/Middle East,
Eastern Europe and large areas of sub-Saharan Africa
and Latin America also experiencing the highest propor-
tion of IHD cases being attributable to major depression
[31]. Conversely, Asia-Pacific, high income, Australasia,
and Asia East were estimated to have the lowest preva-
lence of major depression. The attributable burden age
patterns are also strongly influenced by trends in major
depression prevalence (not shown) [31].
Figure 4 Ischemic heart disease (IHD) disability-adjusted life year (DALY) rates (per 1,000 population) attributable to major depression
by world region for 1990, 2005 and 2010 (age and sex standardized).
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largely due to IHD mortality. This indirectly adds a mor-
tality component to the burden of major depression
seemingly missing from the burden of major depression
[36]. Reassigning attributable DALYs to the direct bur-
den of major depression creates a cumulative burden of
almost 70 million DALYs (Figure 6). As a proportion of
global DALYS, major depression can be revised upwards
to 2.7% from 2.5%.
Discussion
We found a significant increase in risk of developing
IHD in people suffering from major depression (pooled
RR 1.56 (95% CI 1.30 to 1.87)). Almost 4 million, or 3%
of IHD DALYs were attributable to major depression in
2010; the majority of which resulted from premature
death. These findings highlight a previously underes-
timated mortality component of the burden of major
depression.
We used findings from a systematic review and meta-
analysis of observational studies using predetermined
inclusion criteria which attempt to delineate the inde-
pendent relationship of depression leading to incident
IHD from the complex and bidirectional, biological and
behavioral network as described by Stapelberg et al.
[38,39]. Key differences and strengths over previous
reviews are the inclusion of only longitudinal studieswhich exclude, or control for baseline IHD, as well as
measures of depression which closely approximate cli-
nical major depression. Only studies with samples that
could be considered acceptably representative of the
general population were accepted for inclusion. These
criteria are essential in order to most accurately assess
any mental disorder as an independent risk factor for
IHD in the general population.
Findings
All studies that were identified and met our criteria were
prospective cohort studies that were randomized or in-
cluded the entire target population. These provided evi-
dence of a temporal relationship for major depression
preceding IHD, and this is relevant in terms of the vali-
dity of our findings as cross-sectional studies of the rela-
tionship between depression and IHD have been shown
to overestimate the magnitude of the association [12].
The increased risk (RR 1.56, 95% CI 1.30 to 1.87)
found in this review support previous findings. Four
earlier meta-analyses reported pooled relative risk for
depression and incident IHD between 1.57 and 2.69
[6,12,40,41], and major studies such as INTERHEART
[42], which found an OR of 1.44 (95% CI 1.27 to 1.65)
for incident MI.
Statistical power was insufficient for robust subgroup
analyses but a notable finding from exploratory analyses
Figure 5 Ischemic heart disease (IHD) disability-adjusted life years (DALYs) attributable to major depression as a proportion of overall
IHD DALYs by Global Burden of Disease (GBD) study region, 2010.
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of depression measurement tool, with clinical diagnosis
inferring a greater relative risk for the development of
IHD. This could be a reasonable expectation given that
screening tools are likely to capture subthreshold cases
of depression, which may pose a lower risk of developing
incident IHD. Indeed, a dose–response relationship and
a higher risk of IHD in depression meeting diagnosticFigure 6 Cumulative burden of disease of major depression, 2010.thresholds versus symptoms have been shown. The use
of a relative risk attained by pooling diagnostic instru-
ment obtained estimates would have led to PAFs 2.7
times higher than those calculated in this paper resulting
in a large underestimation of attributable burden.
The disproportionate IHD burden attributable to major
depression that is carried by Eastern Europe, Central
Europe and Central Asia infers the need for priority
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these regions. The higher proportions of IHD DALYs seen
in North Africa/Middle East and areas of sub-Saharan
Africa and Latin America also warrant attention where re-
ductions in the prevalence of major depression could
reduce the overall burden of IHD attributable to major
depression.
Time trends are not consistent across regions with
some regions experiencing an increase in burden across
the timepoints and others experiencing a decline. It is
important to note that increases in burden are largely
driven by population growth and ageing, not changes in
actual prevalence rates.
Importantly, these findings add to the incomplete pic-
ture of direct burden for major depression, which did
not include YLL [36]. Our study shows that indirect
pathways of major depression are not only responsible
for significant morbidity but also contribute to prema-
ture mortality via other health outcomes.
Limitations
Estimating the proportion of IHD attributable to major
depression implies a causal relationship between depres-
sion and IHD. This assumption remains to be defini-
tively established. Despite the body of evidence reviewed
here demonstrating an association between depression
and IHD, and observational evidence fulfilling some of
the criteria for causality, the behavioral and biological
drivers of the association remain poorly defined, largely
due to the complex nature of depression and IHD, as
well as the complexity of the relationship between the
two diseases [39]. While a causal relationship between
depression and coronary heart disease is proposed, there
are several related risk factors, for example, smoking,
diet, alcohol consumption, physical activity and obesity,
which likely explain at least part of the association, sup-
ported by the fact that a bidirectional relationship exists
between them [16].
A further potential confounder might also be comor-
bid anxiety [39,43], which itself has a significant rela-
tionship with IHD [43]. Further work is needed to
quantify the relationship between anxiety disorders and
IHD. Generalized anxiety disorder (GAD) is known to
co-occur in 30% to 40% of people with MDD between
the ages of 18 and 65 years [29] and in older people aged
55 to 85 years, 47.5% of those with a MDD also meet
the criteria for at least one anxiety disorder [44]. A
meta-analysis of 20 studies on the association between
anxiety alone and the risk of incident IHD reported a
hazard ratio of 1.26 (95% CI: 1.15 to 1.38; P <0.0001)
and cardiac death hazard ratio of 1.48 (95% CI: 1.14 to
1.92; P = 0.003), independent of demographic variables,
biological risk factors, and health behaviors [45]. Anxiety
and MDD together were also shown predict the risk ofmajor adverse cardiac events risk in patients with IHD
[46]. GAD has further been shown to be a significant
confounder in specific methods used to investigate the
relationship between MDD and IHD, such as heart rate
variability (HRV) [39].
Importantly, one piece of evidence, the hypothesis that
successful depression treatment lowers IHD risk, has not
been proved despite enormous efforts [47]. The Enhan-
cing Recovery in CHD Patients (ENRICHD) randomized
controlled trial in acute coronary syndrome patients
found no greater IHD-risk reduction in the treated
depression arm compared with the control depression
group [48]; other trials were not powered to detect
change in IHD risk [49]. Ongoing trials, such as the
Comparison of Depression Interventions after Acute
Coronary Syndrome (CODIACS) trial will hopefully
test the hypothesis that depression treatment lowers
IHD risk more definitively [50].
In this review and CRA assessment, one study was
from The Netherlands and all other studies originated
from the USA. Only two studies were shown to be na-
tionally representative. This lack of representativeness
makes it difficult to generalize results or determine risk
estimates, population attributable fractions, and attribut-
able risk for populations in other age groups, countries
or regions. Nevertheless, we elected to apply the pooled
relative risk from these two regions to estimate the di-
sease burden of IHD attributable to major depression
worldwide. An underlying assumption of using a consist-
ent measure of risk is that the calculated relative risk is
invariant across countries. Such invariance could be con-
sidered plausible given evidence suggesting that mecha-
nisms which underlie the relationship between MDD
and IHD are primarily biological [6], as are the changes
in behavior associated with MDD, previously thought to
be psychologically driven [51-58], however without data
this cannot be confirmed. The alternative to applying a
universal relative risk across all regions is to exclude 19
of the world’s 21 GBD regions from estimations of at-
tributable burden, however the decision to estimate at-
tributable burden for regions where there was no data
has been a standard position taken by the Global Burden
of Disease Study 2010 [59,60]. While contentious, the
view is taken that to not provide estimates for regions
with missing data is to infer that burden does not exist.
The implications of this are considered unacceptable
and estimates have been produced while simultaneously
calling for action in the research community to fill data
gaps [61].
The lack of targeted risk assessment research in this
area is highlighted by the fact that most data found for
this review originates from a secondary analysis of large
population cohort studies with different primary aims po-
tentially leading to sources of bias. There was significant
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differences in study design, which makes the undertaking
of study comparison and pooling of data difficult and
limits conclusions that can be drawn. The significant he-
terogeneity in study design that exists in this field of
study has been identified in the literature [62]. Add-
itionally, there is also the potential for overestimation
of effect size due to the apparent publication bias to-
wards positive studies.
While any bias due to errors in measurement of major
depression could have been reduced by only accepting
clinical diagnosis or diagnostic interviews, the few stud-
ies that met this criterion would have made the current
review unfeasible. Very few of the studies identified in
our systematic review use well-validated instruments
that reliably provide a diagnosis of major depressive dis-
order. An improvement in the measurement of depres-
sion is an area of opportunity for future research.
GBD 2010 did not include ‘silent’ IHD in its case def-
inition because for the purposes of the study only symp-
tomatic (that is, disabling) diseases were measured. No
studies identified by our review included ‘silent’ IHD. Be-
cause some cases of ‘silent’ IHD were possibly classified
in the ‘no IHD’ group in these studies, the implication is
that these studies underestimated the association be-
tween IHD and depression, making our estimates overly
conservative. These key limitations have been discussed
elsewhere [46].
Given the gender differences in both MDD and IHD
[31,37] and confounding effect of age [63,64], we aimed
to stratify risk by these characteristics. However, dearth
of data did not allow this, necessitating the application
of a summary RR to both males and females across all
age groups (older than 30 years of age). Although it
could be reasonable to expect a higher risk for non-fatal
events over fatal events, the same data restrictions meant
the one RR was applied uniformly to the development of
both YLD and YLL.
Implications
Interactions between mental disorders and a range of
other health outcomes have been widely recognized in
the literature yet mental health is largely missing from
relevant public health policy framework, research prio-
rities and targets for interventions [10]. Given the ac-
cumulating evidence for the role that mental disorders
appear to play in non-communicable disease, the low
treatment rates seen globally warrant review [65].
The European Psychiatric Association aims to increase
the awareness among psychiatrists and primary care
physicians caring for patients with severe mental illness
about the need to screen and treat increased cardiovas-
cular risk factors and diabetes [66]. However, more con-
clusive evidence is needed about the effect of treatmentof mental disorders such as depression in helping decrease
the risk of non-communicable disorders such as IHD.
Nonetheless, the complex and bidirectional relationships
between comorbid mental disorders and cardiovascular
disease require the care for persons with these conditions
to be coordinated and collaborative [67].
Conclusions
This paper comprises the most robust systematic review
of its kind to date and is one of only two comparative risk
assessments assessing major depression as an independent
risk factor for another health outcome [68]. It highlights
the significant association between major depression and
incident IHD, as well as quantifying the impact of depres-
sive illness as an independent risk factor for IHD.
To establish the patterns and nature of the depression
and IHD relationship, the body of evidence needs streng-
thening. Deconstructing the causal network linking de-
pression and IHD is crucial [38,69]. A true understanding
of behavioral and biological pathways, the interrelation-
ship between different risk factors, and mental disorder
comorbidity issues, is needed [19].
Furthermore, there is a need for further well-designed
and targeted research examining mental disorders as in-
dependent risk factors for IHD, particularly in regions
outside of North America, and for the effect of mental
health interventions on incident IHD. Differential risk
levels by gender and age need to be explored in greater
detail.
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